Canada markets close in 3 hours 1 minute

AXSM Sep 2024 60.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
12.500.00 (0.00%)
As of 03:39PM EDT. Market open.
Full screen
Previous Close12.50
Open13.50
Bid18.30
Ask19.90
Strike60.00
Expire Date2024-09-20
Day's Range12.50 - 13.50
Contract RangeN/A
Volume26
Open Interest28
  • GlobeNewswire

    Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New J

  • GlobeNewswire

    Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

    NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is joining the migraine advocacy community to raise awareness of unmet patient needs during Migraine & Headache Awareness Month this June. “Education plays a crucial role in addressing the stigma associated with migraine, a complex neurological disorder often mis

  • GlobeNewswire

    Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

    NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is supporting Alzheimer’s & Brain Awareness Month this June, to help increase awareness and understanding of the challenges Alzheimer’s disease (AD) presents to patients, their caregivers, and their loved ones, and the importance of brain and mental health as cor